At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
68Ga RM2 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating 68Ga RM2, 68Ga-PSMA-11, and 1 other intervention for Prostate Cancer. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsGeneral Electric
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedJan 2019
Primary CompletionMar 2022
TodayJul 2026
First PostedJan 18, 2019
Enrollment StartJan 14, 2019
Primary CompletionMar 8, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.5 years ago
Interventions
68Ga RM2drug
PET radiopharmaceutical
68Ga-PSMA-11drug
PET radiopharmaceutical
Investigational PET scanner coils and softwaredevice
GE Healthcare non-approved PET scanner coils and software